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Original Article
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Abstract
Study Objectives: To compare sleep–wake rhythms, melatonin, and cancer-related fatigue in pediatric patients with acute lymphoblastic leukemia (ALL) to healthy 
children and to assess the association between sleep–wake outcomes and cancer-related fatigue.
Methods: A national cohort of ALL patients (2–18 years) was included. Sleep–wake rhythms were measured using actigraphy and generated the following variables: 
Interdaily stability (IS): higher IS reflects higher stability; intradaily variability (IV): lower IV indicates less fragmentation; L5 and M10 counts: activity counts during 
the five least and 10 most active hours, respectively; and relative amplitude (RA): the ratio of L5 and M10 counts (higher RA reflects a more robust rhythm). The 
melatonin metabolite, 6-sulfatoxymelatonin (aMT6s), was assessed in urine. Cancer-related fatigue was assessed with the PedsQL Multidimensional Fatigue Scale. 
Using regression models sleep–wake rhythms, aMT6s, and cancer-related fatigue were compared to healthy children and associations between sleep–wake outcomes 
and cancer-related fatigue were assessed in ALL patients.
Results: In total, 126 patients participated (response rate: 67%). IS, RA, and M10 counts were lower in patients compared to healthy children (p < 0.001). aMT6s levels 
were comparable to healthy children (p = 0.425). Patients with ALL were more fatigued compared to healthy children (p < 0.001). Lower IS, RA and M10 counts and 
higher IV were significantly associated with more parent-reported cancer-related fatigue. Associations between sleep–wake rhythms and self-reported cancer-related 
fatigue were not statistically significant.
Conclusions: Sleep–wake rhythm impairment is associated with more cancer-related fatigue in pediatric ALL patients. Interventions aimed to improve sleep hygiene 
and encourage physical activity may reduce cancer-related fatigue.
Key words:  actigraphy; acute lymphoblastic leukemia; cancer-related fatigue; physical activity; children sleep–wake rhythms
Statement of Significance
Sleep–wake cycle disruptions are associated with fatigue, amongst many other adverse health outcomes. Cancer-related fatigue is a common and distressing 
side-effect of anti-cancer treatments with few effective interventions available. The exact role of the sleep–wake rhythm in the pathophysiology of cancer-related 
fatigue in pediatric patients is unknown but could provide clues for improvement of cancer-related fatigue. Evidence on sleep–wake rhythms in pediatric cancer 
patients is limited. This study, therefore, aims to compare sleep–wake rhythms and cancer-related fatigue in pediatric patients with acute lymphoblastic leukemia 
(ALL) to healthy children and to evaluate the association between sleep–wake rhythm variables and cancer-related fatigue. The findings of this study suggest op-
portunities for interventions to improve cancer-related fatigue in pediatric patients with ALL.
SLEEPJ, 2020, 1–9
doi: 10.1093/sleep/zsz320
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Introduction
Sleep and wakefulness show a circadian rhythm, which is driven 
by the suprachiasmatic nuclei located in the anterior hypothal-
amus [1]. To align the circadian sleep–wake cycle to the environ-
mental 24-hour light-dark cycle it needs to be synchronized by 
external cues, such as scheduled sleep, physical activity, meals 
and, most importantly, light [1–4]. The ability to maintain a ro-
bust sleep–wake rhythm can be seen as an independent indi-
cator of health [5]. In addition, disruption and misalignment of 
sleep–wake rhythms have been associated with several adverse 
health outcomes, such as, chronic fatigue, impaired cognitive 
functioning, an increased risk of cardiovascular diseases, psy-
chiatric diseases, diabetes and cancer [3, 6–8].
Disturbed sleep–wake rhythms have been reported in adults 
with cancer [9–11]. The severity of these disturbances is associ-
ated with worse cancer-specific outcomes (including impaired 
response to treatment and a decreased survival rate). Also, in 
pediatric patients with acute lymphoblastic leukemia (ALL) and 
with central nervous system (CNS) tumors, impaired sleep-rest 
activity patterns are described [12, 13]. Both in adult cancer pa-
tients and in pediatric cancer patients less robust sleep–wake 
rhythms were linked to more severe cancer-related fatigue [9, 
12, 13].
Cancer-related fatigue is one of the most common side-
effects of cancer treatments that persists after the end of treat-
ment [14–17]. It is a distressing and disabling symptom that 
impairs school functioning and reduces the ability to partici-
pate in social roles and activities [18, 19]. Cancer-related fatigue 
is a multidimensional problem and underlying causal mech-
anisms are not yet well understood. A  biopsychosocial model 
including demographic, biological, medical, functional and be-
havioral factors contributing to cancer-related fatigue seems 
likely [15]. The sleep–wake rhythm, including multiple factors 
of this biopsychosocial model (such as biological and behavioral 
factors), could play a role in the causality of cancer-related fa-
tigue. Therefore, the sleep–wake rhythm could potentially pro-
vide clues to improve cancer-related fatigue in childhood cancer 
patients.
There are several methods of evaluating circadian rhythms. 
Sleep–wake rhythms can unobtrusively be assessed with 
actigraphy. Actigraphy is much less invasive compared to the 
gold standard polysomnography, and in addition, it can record 
sleep–wake patterns continuously over longer periods in an am-
bulant setting [20]. The recorded time-series of activity can be 
analyzed to obtain variables that quantify the fragmentation of 
the sleep–wake cycle, its ability to synchronize to the 24-hour 
light-dark cycle, and levels of daytime and nocturnal physical 
activity.
In addition, the assessment of melatonin has been used as 
an endogenous marker of circadian dysregulations. Melatonin 
production is not influenced by external influences other than 
light, unlike other circadian rhythm markers, and is, therefore, a 
powerful biomarker in the assessment of circadian dysregulation 
[21]. Endogenous disruption of melatonin production is not ex-
pected in pediatric patients with ALL, as structures involved 
in melatonin production and release (such as the suprachias-
matic nucleus and the pineal gland), are generally not affected. 
However, several factors during ALL therapy (such as treatment-
related toxicities and hospitalization) could influence light ex-
posure and subsequently melatonin production [21].
There is limited evidence on sleep–wake rhythms and the 
relation with cancer-related fatigue in pediatric cancer patients 
[12, 13]. Such a relationship could advance our knowledge re-
garding the etiology of cancer-related fatigue and guide the de-
velopment of interventions to improve well-being of pediatric 
cancer patients. Furthermore, melatonin is used in clinical prac-
tice, although it has not been established yet whether melatonin 
levels are actually disturbed in pediatric cancer patients.
Recently, a position paper on behalf of the International 
Psycho-Oncology Society Pediatrics Special Interest Group was 
published with recommendations to expand sleep research in 
pediatric oncology [22]. They recommended to address the gaps 
in understanding the relationship between sleep–wake rhythms 
and health outcomes along the trajectory of pediatric cancer. 
Furthermore, the authors mentioned the need for further re-
search to guide melatonin use in pediatric oncology.
Therefore, this study aims to: (1) Determine sleep–wake 
rhythms, melatonin levels, and cancer-related fatigue in pa-
tients with ALL and compare these outcomes to healthy chil-
dren, and (2) Evaluate the association between sleep–wake 
rhythm variables and cancer-related fatigue.
Methods
Patients and procedures
The results described here are part of the SLAAP [SLEEP]-study 
(SLeep in children with Acute lymphoblastic leukemia And their 
Parents), a multicenter study on sleep(-wake rhythms), quality 
of life and cancer-related fatigue in pediatric patients with ALL 
and functioning of their parents.
The assessment consisted of patient- and parent-reported 
questionnaires (sleep, quality of life, cancer-related fatigue, and 
parental distress), a sleep log, and a 1-week actigraphy assess-
ment. In addition, a first-morning urine void was collected for 
the assessment of 6-sulfatoxymelatonin (aMT6s). Results on 
sleep–wake rhythms, melatonin levels, and cancer-related fa-
tigue are reported here.
Patients were identified through the Dutch Childhood 
Oncology Group (DCOG) registry that includes all pediatric pa-
tients with a diagnosis of cancer or low-grade malignancy in the 
Netherlands. Patients were eligible if they were: (1) treated ac-
cording to the DCOG ALL-11 treatment protocol, and (2) ≥2 years 
of age at assessment. Furthermore, parents and patients needed 
to master Dutch sufficiently to complete the questionnaires. 
Patients were recruited between August 2013 and July 2017 in the 
following Dutch  pediatric oncology centers: Emma Children’s 
Hospital/Academic Medical Center and VU University Medical 
Center Amsterdam, Wilhelmina’s Children’s Hospital/University 
Medical Center Utrecht, Princess Máxima Center for pediatric 
oncology Utrecht, Sophia Children’s Hospital/Erasmus Medical 
Center Rotterdam, Beatrix Children’s Hospital/University 
Medical Center Groningen, Amalia Children’s Hospital/Radboud 
University Medical Center Nijmegen. Parents and patients of 
12 years or older provided informed consent for participation.
The assessment was planned after the first treatment phase 
(i.e. induction and re-induction therapy), which lasted about 
3  months and is considered the most intensive phase of ALL 
therapy. During the study assessment, ALL treatment consisted 
of four 2-week courses. Each course started with an approxi-
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of high dose methotrexate. The assessment was performed 
in-between admissions, in a home setting. During these 
intervals, patients only received oral anti-cancer medication 
(mercaptopurine) and generally experienced little treatment-
related toxicity. Glucocorticoid therapy, a hallmark of ALL treat-
ment and known for its effects on sleep, was not used during 
this treatment phase [12, 23, 24]. According to the ALL-11 
protocol patients are stratified to the following risk groups (with 
increasing treatment intensity) based on response to treatment 
and cytogenetics: standard risk, medium risk, and high risk. At 
the time of the study assessment, most patients are not yet in-
formed about their risk group stratification. Treatment did not 
include cranial radiation for any of the patients at time of the 
study assessment. Given the intensity of treatment and the 
regular hospital admissions patients generally do not attend 
school in this period.
The Institutional Review Board of the Erasmus Medical 
Center approved this study.
Measures
A survey regarding socio-demographics was completed by 
parents. Cancer-related fatigue was assessed by the valid and 
reliable questionnaire mentioned below. Since young or very 
ill patients are not able to fill out questionnaires themselves, 
parent-proxy reports were collected for all participants. In add-
ition, self-reports were filled out by participants aged 8  years 
and older. Questionnaires were completed paper-pencil or 
through a secured online web portal depending on parent/pa-
tient preference. Parents only reported on child functioning, par-
ental functioning was not described here. Sleep–wake rhythm 
variables were calculated based on a 7-day actigraphy assess-
ment (all ages).
Socio-demographic information
Information on the following patient variables was collected: 
age, sex, time since diagnosis, parent-reported pre-existent 
sleep problems (yes or no), comorbidity (yes or no), sleep medi-
cation use (yes or no), bedroom sharing (yes or no).
Parents provided information on the following parental 
socio-demographics: parental age, sex, and highest attained 
educational level. Educational level was defined according to 
Statistics Netherlands (low educational level  =  no education, 
primary school, lower secondary education; middle educa-
tional level  =  upper secondary education, pre-university edu-
cation, intermediate vocational education; high educational 
level  =  higher vocational education, university) [25]. For ana-
lyses, educational level was dichotomized as lower (low and 
middle educational level) versus higher educational level (high 
educational level).
Actigraphy derived sleep–wake rhythm
Actigraphy assessments were used to calculate sleep–wake 
rhythm variables. An actigraph (ActiGraph wGT3X-BT, 
Pensacola, FL) is a nonintrusive device that measures the oc-
currence and intensity of limb movements. Actigraphy has been 
validated against polysomnography and has proven to be an 
adequate method to measure sleep–wake patterns in infants, 
children, and adolescents [20, 26, 27]. Patients were instructed 
to wear the actigraph on their wrist for 24-hours for 7 days and 
to record sleep–wake schedule information (bedtime, wake time, 
nap times, non-wear times) in a sleep log to facilitate correct 
interpretation of the actigraphy data. With visual inspection of 
the data and based on sleep logs, invalid data was identified 
and removed from further analysis. Data was considered in-
valid in case probable non-wear time exceeded 3 consecutive 
hours [5]. A 24-hour period starting at the onset of this non-wear 
time was then removed from further analysis [5]. Sleep–wake 
rhythm variables were calculated only if valid data was avail-
able for at least 72 hours [28]. There are different approaches 
to quantify sleep–wake actigraphic recordings. Two commonly 
used methods are the cosinor analysis and the nonparametric 
method. Cosinor analysis fits a 24-hour cosine wave to the data 
and provides the estimated phase and amplitude. The method 
is parametric and presumes that the activity level variation 
over the day is best described with a 12:12 hour symmetrical 
sinusoidal. However, the sleep–wake rhythm is far from sym-
metrical and sinusoidal. In adults and adolescents, for example, 
there is an asymmetrical distribution of about 8 hours of sleep 
and 16 hours of wakefulness and in infants periods of sleep and 
wakefulness are more alternating over 24-hours. To better ac-
commodate the non-sinusoidal, asymmetric activity pattern of 
everyday life, nonparametric methods have been proposed that 
do not make assumptions about the distribution of the rhythm. 
Accordingly, the nonparametric method seems to describe the 
sleep–wake pattern more accurately than cosinor analysis [28]. 
The following sleep–wake rhythm variables were obtained using 
nonparametric methods (definitions are provided in Table  1) 
[29]: Interdaily stability (IS), Intradaily variability (IV), M5 counts, 
M10 counts, and relative amplitude (RA).
These variables were also obtained in healthy children aged 
2–18 years with the same type of actigraph: ActiGraph wGT3X-BT, 
Pensacola, FL. Children were not eligible if they visited a health 
care provider for sleep disturbances in the preceding 3 months, 
used any type of sleep medication (including melatonin), or had 




0–2 An estimate of the 24-hour rest-
activity rhythm and reflects the 
fragmentation of the rhythm, a 
higher intradaily variability indicates 
a more fragmented rhythm
Interdaily 
stability 
0–1 An estimate of the stability of the 
rhythm, and describes the synchron-
ization of the rhythm, wherein 1 
signifies a perfect synchronization to 
the light-dark cycle
L5 counts 0–∞ Activity counts of the least active 5 
hours of the day.
M10 counts 0–∞ Activity counts of the most active 10 
hours of the day.
Relative 
amplitude 
0–1 Ratio of the difference and the sum of 
M10 and L5 counts. A higher relative 
amplitude indicates a bigger differ-
ence between the least and most 
active period during the day, hence a 
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a medical condition that could potentially affect their sleep(–
wake rhythm). These healthy children were not matched to the 
study population described here, but analyses were controlled 
(as described below) for factors that could potentially affect the 
outcomes of the current study. Valid actigraphy data was avail-
able for 85 healthy children (median age: 8.5 years [interquartile 
range 5.5–15.3], 50.6% boys, highest parental educational level: 
34.1% lower educational level and 65.9% higher educational 
level). Additional information on the recruitment, in- and exclu-
sion criteria, and socio-demographics of the sample of healthy 
children is provided as Supplementary Material.
Urinary aMT6s
Metabolites of melatonin can be easily assessed in blood, saliva, 
and urinary samples. Melatonin levels show intra-individual sta-
bility but inter-individual variability [30]. In-home salivary sam-
pling has shown to be a feasible method for the assessment of 
dim-light melatonin onset (DLMO) in pediatric cancer patients 
[31]. However, considering the young age of most ALL patients, 
the multiple study assessments (questionnaires, actigraphy, 
melatonin), and the timing of assessment during treatment, the 
burden of salivary DLMO assessment was considered too high. 
To reduce the study burden, a single morning urine sample was 
therefore used for the assessment of aMT6s, as this highly cor-
relates with total nocturnal plasma melatonin levels [21, 32, 33]. 
Patients and parents were instructed to collect the first-morning 
void urine in the second part of the measurement week. Since 
urinary aMT6s levels are significantly correlated when compared 
on consecutive days, urine collection was not restricted to a spe-
cific day during the measurement week [21]. Patients and parents 
were asked to store the urine in the refrigerator until the sample 
was returned to the research team. Bojkowski et al. [34] showed 
stable aMT6s levels even at room temperature for 5 days. Urine 
samples were stored at −80°C until analysis. Stability of aMT6s 
levels over time has been proven and it is, therefore, suitable for 
delayed laboratory processing [21]. The aMT6s levels were ana-
lyzed by isotope dilution mass spectrometry using online solid-
phase extraction in combination with liquid chromatography 
and tandem mass spectrometry (LC–MS/MS), at the Department 
of Laboratory Medicine, University Medical Center Groningen. 
Intra-assay imprecision was below 2.5% and inter-assay impreci-
sion was below 5.4%. The quantification limit for aMT6s was de-
termined at 0.2 nmol/L. Concentrations of aMT6s were adjusted 
for urinary creatinine levels. In the sample of healthy children 
mentioned above (Supplemental Material), morning void urine 
samples were collected to provide age-appropriate urinary aMT6s 
levels in healthy children. Valid aMT6s values were available for 
90 healthy children (median age: 8.9 years [5.6–15.7], 52.2% boys).
Cancer-related fatigue
The Dutch version of the PedsQL Multidimensional Fatigue Scale 
(PedsQL MFS) was used to assess cancer-related fatigue [35, 36]. 
The PedsQL MFS is designed to measure child and parent per-
ceptions of fatigue in pediatric patients. The questionnaire con-
sists of 18-items and assesses the occurrence of problems during 
the past week. A 5-point Likert scale (almost always, frequent, 
sometimes, almost never, never) is used. The items allow for an 
overall fatigue score and three subscales scores (each six items): 
general fatigue (e.g.: “I feel tired” or “I feel too tired to spent time 
with my friends”), sleep-rest fatigue (e.g.: “I spent a lot of time 
in bed” or “I feel tired when I  wake up in the morning”), and 
cognitive fatigue (e.g.: “It is hard for me to keep my attention on 
things” or “It is hard for me to remember more than one thing at 
a time”). Items are rescored to a 0–100 score. A higher score is in-
dicative of better functioning, that is, less cancer-related fatigue. 
The subscale scores were used in this study. Scores in healthy 
Dutch children have previously been collected [35]. The original 
dataset of this population was used for analyses. The internal 
consistency of the subscales was adequate in Dutch healthy 
children as well as in current study population (Cronbach’s 
alpha: parent-reports > 0.70 and self-reports > 0.60).
Statistical analysis
Mann Whitney U tests and chi-square tests were used to assess 
differences in patient age and sex between participants and non-
participants and patients that were not invited for the study.
Descriptive statistics of sleep–wake rhythm variables, 
urinary aMT6s values corrected for creatinine levels (µmol/mol 
creatinine), and cancer-related fatigue scores were presented. 
Patients’ outcomes were compared to outcomes of healthy chil-
dren using linear regression models. Regression models were 
adjusted for patient age, sex, and sleep medication use as differ-
ences in these outcomes between patients with ALL and healthy 
children could affect sleep–wake rhythm outcomes, melatonin 
levels, and cancer-related fatigue. The regression models for 
sleep–wake rhythm outcomes and cancer-related fatigue were 
also adjusted for highest attained parental educational level. 
Patients with ALL that used melatonin were excluded from 
the urinary aMT6s analysis. Differences between patients and 
healthy children were expressed in a regression coefficient (B) 
with a 95% confidence interval (CI).
Additionally, concordance between parent- and self-reported 
cancer-related fatigue scores was determined with Pearson or 
Spearman correlation coefficients as appropriate. Correlations 
between 0.2 and 0.5 were considered small, 0.5–0.8 moderate, 
and ≥0.8 strong.
Associations between sleep–wake rhythm variables and 
cancer-related fatigue were evaluated with linear regression 
models. Models were adjusted for age, sex, and sleep medication 
use. The adjusted regression coefficient (B) with a 95% CI were 
presented to express the magnitude of the association.
IBM SPSS statistics version 22.0 was used for all analysis. 




Of the 276 patients that were eligible for the study according 
to the DCOG registry, 225 were invited to participate (Figure 1). 
Fifty-one patients were not invited for the study, mainly be-
cause of a severe course of the disease or logistical reasons. 
Informed consent was provided for 151 patients (response rate 
67%). The perceived burden of the study was the main reason 
for non-participation. At least one of the study assessments was 
completed by 126 children (parent-reports n = 122, self-reports 
n = 33, actigraphy n = 71, urine samples n = 78). Parent-reports on 
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assessment were completed by 55 participants, of whom 20 par-
ticipants also completed self-reports.
Baseline characteristics
Age and sex were not statistically different between participants 
and non-participants and those not invited for the study (Table 2).
Sleep medication was used by 8 participants at time of the 
study: melatonin (n = 5), lorazepam (n = 1), unknown (n = 2). In 19 
patients, pre-existent sleep problems were reported by parents 
and these consisted of problems with initiating and maintaining 
sleep (n  =  15), somnambulating (n  =  1), need of sibling in the 
room (n = 1), and two parents reported less need for sleep than 
other children.
The median age at diagnosis of patients that completed self-
reports was 12.2 years (age range [min–max]: 7.5–17.9), 5.9 years 
(age range: 1.9–17.9) for those with valid sleep–wake rhythm 
data (actigraphy derived) and 6.1 years (age range: 2.3–17.9) for 
patients with valid urinary aMT6s levels. Somewhat more girls 
participated in the actigraphy assessments (46.5%) compared to 
the total population. Time since diagnosis was comparable to 
the total population in those who participated in self-reports, 
actigraphy, and urinary assessments.
Actigraphy derived sleep–wake outcomes
Patients with ALL had a significantly lower IS and RA compared 




Physician decision/paent burden n=7
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sleep–wake rhythm (Table  3). M10 counts were significantly 
lower in ALL patients. IV and M5 counts were not significantly 
different from healthy children.
Urinary aMT6s values
In patients with ALL, the mean aMT6s value was 26.70 (SD: 
20.64) µmol/mol creatinine, compared to 24.15 (SD: 19.69) µmol/
mol creatinine in healthy children. Adjusted for age and sex, 
urinary aMT6s levels were not statistically different between 
patients and healthy children (B −2.12 (95% CI): (−7.35; 3.11) 
p-value: 0.425).
Cancer-related fatigue
Parent-reported general and sleep-rest fatigue scores were sig-
nificantly lower (indicating more cancer-related fatigue) in pa-
tients with ALL compared to scores in healthy children, while 
scores on the cognitive fatigue scale were comparable (Table 4). 
Self-reported general fatigue scores were significantly lower in 
ALL patients, whereas sleep-rest and cognitive fatigue scores 
were not significantly different from scores in healthy children. 
In families where parent-proxy and child dyad reports were 
available, parent-proxies reported somewhat lower general fa-
tigue scores (58.3 interquartile range [IQR]: 39.6–75.0) but similar 
sleep-rest (72.0  ± 15.5) and cognitive fatigue scores (72.9 [IQR: 
62.5–95.8]) compared to child self-reports. Concordance between 
parent-proxy and child dyads was moderate (correlation coeffi-
cients 0.56–0.65, p < 0.01).
Association between sleep–wake rhythms and 
cancer-related fatigue
A higher IS (i.e. more stable rhythm), a higher RA (i.e. more 
robust rhythm), and higher M10 counts (i.e. more physical ac-
tivity during the day) were all significantly associated with 
higher parent-reported general and sleep-rest fatigue scores 
(indicating less fatigue) (Table  5). Higher IV (i.e. more frag-
mented rhythm) was significantly associated with lower 
parent-reported sleep-rest fatigue scores (indicating more 
fatigue). L5 counts were not significantly associated with 
parent-reported cancer-related fatigue. None of the sleep–
wake rhythm variables were significantly associated with 
self-reported cancer-related fatigue.
Table 2. Baseline characteristics




Not invited  
N = 51
Child- and treatment-related factors
 Child age at diagnosis—Median [IQR] 5.1 [3.1; 9.3] 5.5 [3.5; 11.9] 5.8 [3.8; 11.5]
 Female child sex—N (%) 51 (40.5) 42 (42.1) 23 (45.1)
 Time since diagnosis in months—Median [IQR] 4.5 [4.1; 5.1]   
 Preexisting sleep problems—N (%) 19 (15.1)   
 Use of sleep medication—N (%) 8 (6.3)   
 Comorbid chronic illness—N (%)a 8 (6.3)   
 Sharing a bedroom—N (%) 26 (20.6)   
Parental- and family factors 
 Parental age 37.0 [34.0; 43.0]   
 Female parental sex—N (%) 98 (77.8)   
 Educational level—N (%)    
  Low 5 (4.0)   
  Middle 36 (28.6)   
  High 82 (65.1)   
  Unknown 3 (2.4)   
 Country of birth—N (%)    
  Netherlands 116 (92.1)   
  Otherb 7 (5.6)   
  Unknown 3 (2.4)   
aDown syndrome (n = 3), autism (n = 1), hypermobility (n = 1), coeliac disease (n = 1), anorectal malformation (n = 1), and cavernomas in the brain (n = 1).
bBrazil (n = 1), Kenya (n = 1), Romania (n = 1), South Africa (n = 1), Surinam (n = 2), and Turkey (n = 1).
Table 3. Sleep–wake rhythm variables (actigraphy derived) in patients with ALL compared to healthy children.
Patients with ALL (N = 71)  
mean ± SD or median [IQR]
Healthy children (N = 85)  
mean ± SD or median [IQR] B(95% CI)a p-value
Interdaily stability 0.58 ± 0.13 0.62 ± 0.13 −0.07 (−0.10; −0.04) <0.001
Intradaily variability 0.74 ± 0.24 0.72 ± 0.20 0.06 (−0.01; 0.12) 0.070
Relative amplitude 0.92 ± 0.05 0.95 ± 0.03 −0.03 (−0.04; −0.02) <0.001
L5 counts 48.6 [36.4–72.8] 46.3 [36.2–63.5] 3.0 (−5.5; 11.5) 0.485
M10 counts 1752.5 ± 758.3 2187.1 ± 709.3 −599.5 (−784.2; −414.7) <0.001







niversity Library user on 24 D
ecem
ber 2020
Steur et al. | 7
Discussion
This study provides unique information on sleep–wake rhythms, 
melatonin levels, cancer-related fatigue and the association be-
tween sleep–wake rhythm variables and cancer-related fatigue 
in a large sample of pediatric patients with ALL, after the first, 
most intensive phase of therapy, when a first recovery of the dis-
ease and treatment can be expected.
The stability and robustness of the sleep–wake cycle were 
reduced in pediatric patients with ALL compared to healthy chil-
dren. Furthermore, they were less active during the day. There 
may be several reasons for the reduced stability and robustness 
of the rhythm. First, the activity levels may be low overall after 
the intensive first part of therapy, when most patients are not 
yet able to participate in social activities, sports activities, and to 
attend school. Second, as mentioned previously, external stimuli 
are needed to synchronize the biological clock to the light-dark 
cycle and in pediatric patients treated for ALL some of these 
stimuli could be disrupted [3]. For example, parents of ALL pa-
tients may be more lenient with limit setting and the reinforce-
ment of rules with regards to sleep hygiene [37, 38].
Daytime napping fragments the sleep–wake rhythm and has 
been described in pediatric patients with ALL [23, 24]. However, 
fragmentation was not found in our study. The low physical ac-
tivity levels in our sample could have led to less fragmentation 
of the rhythm. Furthermore, assessments were planned in home 
setting in a phase with less treatment-related toxicity, enabling 
a first recovery, which might have reduced the fragmentation 
of the rhythm. Moreover, patients in the previous studies that 
reported fragmentation were on maintenance treatment and 
received dexamethasone, whereas assessments in the current 
study took place in a period without glucocorticoids [23, 24].
Melatonin levels were comparable to healthy children. 
Shifted light–dark exposure affects melatonin production 
[21]. Disturbed melatonin production and release as a re-
sult of the reduced sleep–wake rhythm stability in our study 
population could have been expected, but was not found. 
However, although morning aMT6s highly correlate with noc-
turnal peak melatonin levels, DLMO cannot be assessed with 
a single morning urine collection. The DLMO may therefore 
still be different in pediatric patients with ALL compared to 
healthy children. Melatonin was used in 4% (5/125) of the pa-
tients in the current study. Melatonin is available over the 
counter in the Netherlands and clinicians are therefore not 
always aware of the use of melatonin. However, as melatonin 
is only indicated in patients with circadian rhythm disorders, 
it is not only important that clinicians are aware of melatonin 
supplementations but also that they should be cautious in pre-
scribing melatonin. Although melatonin may seem relatively 
safe, possible late effects of long-term use during early develop-
ment are insufficiently known. Moreover, incorrect dosing and 
timing of exogenous melatonin can affect the biological clock 
and cause adverse circadian phase shifting [39]. Prescription of 
melatonin by a healthcare provider that is familiar with mela-
tonin and circadian rhythm disorders is, therefore, advised [39]. 
Furthermore, non-medicated options (such as timed bright 
light and dim light manipulations) should also be considered 
to support endogenous melatonin release in individual cases 
where the circadian rhythm is disturbed [39].
Table 4. Cancer-related fatigue (PedsQL MFS scores) in patients with ALL compared to healthy children
PedsQL MFS scale
Patients with ALL  
mean ± SD or median [IQR]
Healthy children [33]  
mean ± SD or median [IQR] B (95% CI)a p-value
Parent reports N = 122 N = 497   
 General fatigue 56.61 ± 25.51 83.33 [70.83–91.67] −25.60 (−29.11; −22.10) <0.001
 Sleep-rest fatigue 70.83 [56.25–83.33] 87.50 [75.00–95.83] −16.11 (−19.40; −12.82) <0.001
 Cognitive fatigue 75.00 [66.67–95.83] 79.17 [66.67–95.83] −1.29 (−5.04; 2.47) 0.502
Self-reports N = 33 N = 298   
 General fatigue 70.83 [50.00–83.33] 79.17 [70.83–91.67] −12.86 (−18.47; −7.25) <0.001
 Sleep-rest fatigue 70.38 ± 15.99 74.60 ± 14.84 −4.59 (−10.30; 1.28) 0.115
 Cognitive fatigue 75.00 [56.25–91.67] 79.17 [66.67–91.67] −5.64 (−12.52; 1.24) 0.108
aAdjusted for patient age, sex, sleep medication use, and highest attained parental educational level.
Table 5. Association between sleep–wake rhythm variables (actigraphy derived) and cancer-related fatigue (PedsQL MFS scores)
B (95% CI)a B (95% CI)a B (95% CI)a
Parent reports (n = 69) General fatigue Sleep-rest fatigue Cognitive fatigue
 Interdaily stability (0.1 change) 5.53 (0.06; 10.99)* 4.87 (0.90; 8.84)* −1.21 (−5.44; 3.02)
 Intradaily variability (0.1 change) −2.02 (−4.92; 0.89) −2.59 (−4.66; −0.52)* −0.004 (−3.17; 3.16)
 Relative amplitude (0.1 change) 16.12 (2.97; 29.26)* 14.06 (4.56; 23.55)* −0.77 (−11.12; 9.59)
 L5 counts (10 counts change) 0.00 (−2.18; 2.19) 0.10 (−1.51; 1.71) −0.22 (−1.87; 1.42)
 M10 counts (10 counts change) 0.18 (0.08; 0.28)** 0.16 (0.09; 0.23)** 0.02 (−0.06; 0.10)
Self-reports (n = 24) General fatigue Sleep-rest fatigue Cognitive fatigue
 Interdaily stability (0.1 change) −0.94 (−8.90; 7.03) 3.46 (−3.94; 10.87) −5.76 (−14.58; 3.06)
 Intradaily variability (0.1 change) −1.60 (−4.63; 1.43) −2.42 (−5.15; 0.31) 0.81 (−2.81; 4.42)
 Relative amplitude (0.1 change) 8.32 (−10.76; 27.40) 9.38 (−8.62; 27.37) 0.34 (−22.32; 23.01)
 L5 counts (10 counts change) 0.82 (−3.03; 4.68) 2.25 (−1.27; 5.77) −0.57 (−5.06; 3.93)
 M10 counts (10 counts change) 0.07 (−0.10; 0.24) 0.13 (−0.02; 0.29) −0.12 (−0.32; 0.07)
aAdjusted for patient age, sex, sleep medication use and highest attained parental educational level.
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In accordance with literature, more cancer-related fatigue 
was reported in this ALL population, with the exception of cog-
nitive cancer-related fatigue [14, 16]. The absence of cognitive 
cancer-related fatigue, which is in line with a previous study in 
adolescents with cancer, is possibly due to the lower cognitive 
demands and expectations in this early phase of therapy [16]. 
Similar as in pediatric patients with ALL during maintenance 
treatment, a more impaired sleep–wake rhythm was associated 
with higher levels of parent-reported cancer-related fatigue [12]. 
Furthermore, we confirmed a previously reported association 
between increased cancer-related fatigue and lower physical ac-
tivity levels [40, 41].
The association with sleep–wake outcomes was not found 
for self-reported cancer-related fatigue. The small number of 
available self-reports could have limited the sensitivity to find 
a significant association. Moreover, differences in patient- and 
parent-reported outcomes are common [42–44]. Coping mechan-
isms differ for patients and parents. Patients may change their 
judgment of symptoms during the course of a cancer treatment, 
described as “response shift,” while parents may overreport 
symptoms due to concerns about their child’s health [37, 42, 45].
Given the many adverse health outcomes and even the 
worse cancer-related outcomes that have been associated with 
impaired sleep–wake rhythms in studies on adults, efforts 
to improve sleep–wake rhythms in pediatric cancer patients 
are important [3, 10, 11]. More stringent bedtime routines and 
participation in appropriate levels of physical activity as soon 
as possible might enhance the robustness of the sleep–wake 
rhythm. Clinicians should, therefore, be aware of healthy sleep 
behaviors and pay attention to sleep hygiene and physical ac-
tivity in this population. Interventions combining sleep hygiene 
education and physical activity may enhance the sleep–wake 
rhythm and have already proven feasibility and acceptability in 
pediatric patients with ALL [46, 47]. Furthermore, the association 
between physical activity and cancer-related fatigue implicates 
that such interventions may provide opportunities to improve 
cancer-related fatigue in this population.
This study provides valuable additional information to 
the existing literature, as it is the first study in pediatric pa-
tients with ALL to examine sleep–wake rhythm variables using 
nonparametric methods and to determine melatonin levels. 
However, some limitations of the study needs to be mentioned. 
First, not all patients participated in all study assessments (ques-
tionnaires, actigraphy, and melatonin assessment). Hence, par-
ticipation bias, for example, based on treatment toxicity, cannot 
completely be ruled out. The study may, therefore, have under-
estimated sleep–wake rhythm disturbances and cancer-related 
fatigue. Second, because of the small sample of available self-
reports these results should be interpreted with caution. Third, 
families with a higher level of education were overrepresented 
in our sample compared to the general Dutch population [25]. 
Since a lower socio-economic status has been associated with 
less healthy sleep behaviors, our study may have underesti-
mated the prevalence and severity of disturbed sleep–wake 
rhythms [48]. Finally, nocturnal enuresis was not registered. 
Obtaining first-morning aMT6s levels, we possibly have not cap-
tured the total melatonin secretion in children with nocturnal 
enuresis. With this method, we might, therefore, have underesti-
mated aMT6s levels. However, Wada et al. [49] reported similar 
associations between aMT6s levels and socio-demographics in 
their total sample as compared to the subgroup of children that 
probably did not urinate during the night.
In conclusion, pediatric patients with ALL have a less stable and 
less robust sleep–wake rhythm, are less physically active and ex-
perience more cancer-related fatigue after the first, most intensive 
phase of therapy. Sleep–wake rhythm impairment is associated with 
increased levels of cancer-related fatigue in these patients. Clinicians 
should, therefore, pay attention to sleep hygiene and stimulate phys-
ical activity guided by the physical condition of patients. Longitudinal 
studies are important to unravel the development of the association 
between sleep–wake rhythms and cancer-related fatigue during and 
after treatment. Furthermore, interventions aiming at improving 
sleep hygiene and encouraging physical activity as early as possible 
are needed, to eventually reduce cancer-related fatigue, a common 
and distressing symptom in pediatric oncology patients.
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